Efficacy and Safety of Allopurinol and Febuxostat in Patients With Gout and CKD: Subgroup Analysis of the STOP Gout Trial

非布索坦 医学 痛风 别嘌呤醇 子群分析 内科学 高尿酸血症 重症监护医学 尿酸 荟萃分析
作者
Lindsay N. Helget,Anne Davis‐Karim,James R. O’Dell,Ted R. Mikuls,Jeff A. Newcomb,Maria Androsenko,Mary T. Brophy,Bryant R. England,Ryan Ferguson,Michael H. Pillinger,Tuhina Neogi,Hongsheng Wu,Paul M. Palevsky
出处
期刊:American Journal of Kidney Diseases [Elsevier]
被引量:1
标识
DOI:10.1053/j.ajkd.2024.04.017
摘要

Rationale & Objective We conducted a prespecified examination of the efficacy and safety of allopurinol and febuxostat administered using a treat-to-target strategy in trial participants with chronic kidney disease (CKD). Study Design Prespecified sub cohort analysis of a randomized controlled trial. Setting & Participants: A sub study of the STOP Gout trial in participants with CKD. CKD was defined as an eGFR 30-59 mL/min/1.73 m2 at baseline. Exposure Trial participants with CKD and gout and serum urate (sUA) concentration ≥6.8 mg/dL were randomized 1:1 to receive allopurinol or febuxostat. Urate lowering therapy (ULT) was titrated during weeks 0-24 to achieve a goal sUA of <6.0 mg/dl (<5.0 mg/dl with tophi) (Phase 1) and maintained during weeks 25-48 (Phase 2). Gout flare was assessed between weeks 49-72 (Phase 3). Outcome Gout flare between weeks 49-72 (Phase 3) was the primary outcome. Secondary outcomes included sUA goal achievement and ULT dosing at end of Phase 2, and serious adverse events (SAEs). Analytical Approach Outcomes between treatment groups were compared using logistic regression models for binary outcomes, and Poisson regression for flare rates. Multivariable models were subsequently used, adjusting for factors identified to be imbalanced by treatment arm. Results 351 of 940 participants (37.3%) had CKD; 277 were assessed for the primary outcome. Fewer patients randomized to allopurinol had a flare during phase 3 (32% vs 45%; p=0.02) despite similar attainment of sUA goal (79% vs. 81%; p=0.6) by the end of Phase 2. Acute kidney injury (AKI) was more common in participants with stage 3 CKD randomized to allopurinol compared to febuxostat. Limitations Limited power to assess infrequent safety events, largely male, older population. Conclusions Allopurinol and febuxostat are similarly efficacious and well-tolerated in the treatment of gout in people with CKD when used in a treat-to-target regimen.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
只喝白开水完成签到 ,获得积分10
2秒前
超体完成签到 ,获得积分10
4秒前
LouieHuang发布了新的文献求助10
7秒前
六一儿童节完成签到 ,获得积分10
11秒前
只爱医学不爱你完成签到 ,获得积分10
12秒前
orixero应助LouieHuang采纳,获得10
19秒前
王QQ完成签到 ,获得积分10
20秒前
细心的如天完成签到 ,获得积分10
21秒前
icewuwu完成签到,获得积分10
21秒前
QiaoHL完成签到 ,获得积分10
22秒前
reset完成签到 ,获得积分10
28秒前
微雨若,,完成签到 ,获得积分10
31秒前
hanhan完成签到 ,获得积分10
32秒前
uon完成签到,获得积分10
34秒前
misstwo完成签到,获得积分10
36秒前
秀丽的皮皮虾完成签到 ,获得积分10
36秒前
37秒前
黄花菜完成签到 ,获得积分10
40秒前
开心叫兽完成签到 ,获得积分10
41秒前
wyw完成签到 ,获得积分10
44秒前
雍元正完成签到 ,获得积分0
44秒前
巾凡完成签到 ,获得积分10
44秒前
Mason完成签到,获得积分10
46秒前
48秒前
LouieHuang发布了新的文献求助10
51秒前
彭超完成签到 ,获得积分10
59秒前
slsdianzi完成签到,获得积分10
1分钟前
LouieHuang完成签到,获得积分10
1分钟前
为什么不学习完成签到,获得积分10
1分钟前
优雅含灵完成签到 ,获得积分10
1分钟前
1分钟前
Liberal-5完成签到 ,获得积分10
1分钟前
勤恳的TT完成签到 ,获得积分10
1分钟前
那些兔儿完成签到 ,获得积分10
1分钟前
小卷粉完成签到 ,获得积分10
1分钟前
开放又亦完成签到 ,获得积分10
1分钟前
小刺猬完成签到,获得积分10
1分钟前
小静完成签到 ,获得积分10
2分钟前
105完成签到 ,获得积分10
2分钟前
jzs完成签到 ,获得积分10
2分钟前
高分求助中
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
Chen Hansheng: China’s Last Romantic Revolutionary 500
宽禁带半导体紫外光电探测器 388
Case Research: The Case Writing Process 300
Global Geological Record of Lake Basins 300
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3142849
求助须知:如何正确求助?哪些是违规求助? 2793732
关于积分的说明 7807164
捐赠科研通 2450021
什么是DOI,文献DOI怎么找? 1303576
科研通“疑难数据库(出版商)”最低求助积分说明 627016
版权声明 601350